Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 20;9(9):e031341. doi: 10.1136/bmjopen-2019-031341

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Daily dose of the index NOAC prescription by degree of renal impairment^* for (A) new users of apixaban, (B) new users of dabigatran and (C) new users of rivaroxaban, in patients with NVAF and no other recent indication. Renal function was unknown in 13.6% of the apixaban cohort, 12.3% of the dabigatran cohort and 13.0% of the rivaroxaban cohort. ^*Estimated using the chronic kidney disease epidemiology collaboration equation. eGFR, estimated glomerular filtration rate; NOAC, non-vitamin K antagonist oral anticoagulant; NVAF, non-valvular atrial fibrillation.